Strategic Funding FAST is a major funder of Angelman syndrome research with annual revenue in the multi-million range, presenting opportunities to position partnerships around grant-driven research programs and co-funded initiatives.

Research Collaboration Recent partnerships with Apertura Gene Therapy to access advanced delivery technologies indicate FAST openness to tech-enabled therapeutics and cross-sector collaborations that could be expanded to gene therapy, CNS delivery, or biomarker research.

Clinical Translation FAST supports projects across the drug development spectrum, including translational and clinical trial efforts, signaling potential for services or products that accelerate bench-to-bedside timelines, such as study design support, trial infrastructure, or patient recruitment networks.

Digital Engagement With a tech stack spanning AWS, WordPress, Microsoft 365, and engagement tools (Asana, Hootsuite, Constant Contact), there is opportunity to offer donor and patient engagement platforms, data analytics, and program management services to optimize outreach and impact tracking.

Strategic Giving Significant philanthropic backing from FAST (notably donations to research centers) suggests potential for corporate partnerships, sponsorships, or matching gift programs aligned with rare neurodevelopmental disorder initiatives and patient advocacy.